146510-36-3 Usage
Description
In July 2015,
olanexidine gluconate, a biguanide compound with remarkable
antibacterial activity, was approved by the Pharmaceuticals and
Medical Devices Agency (PMDA) of Japan for skin antisepsis
at surgical sites. The drug was developed and marketed by
Otsuka Pharmaceutical in Japan and is available as topical
solution (1.5%). Olanexidine gluconate exhibited efficacy
against a wide range of bacterial strains, especially Grampositive
bacteria. In vitro experiments exploring its mechanism
of action indicated that olanexidine interacts with bacterial
surface molecules (such as lipopolysaccharides and lipoteichoic
acid), disrupting the cell membranes of liposomes. These
models suggest that the drug permeates the membranes of both
Escherichia coli and Staphylococcus aureus and denatures proteins
at relatively high concentrations (>160 g/mL).
Synthesis
The synthesis of olanexidine gluconate is relatively
straightforward, involving the linkage of an n-octyl side chain
and a dichlorobenzylamine through a bis-guanidyl lynchpin.
The synthesis began with the reaction of commercial noctylamine
(17) with sodium dicyanamide in the presence of
concentrated sulfuric acid in refluxing n-butyl acetate to give
rise to 1-cyano-3-octylguanidine (18) in 86% yield .
Conditions employed to subsequently secure biguanidine 20 as
the HCl salt hemihydrate in 77% yield were nearly identical to
those used for the conversion of 17 to 18. Finally, treatment of
20 with sodium hydroxide in the presence of gluconic acid (21)
gave rise to olanexidin gluconate (II) in almost quantitative
yield.
Check Digit Verification of cas no
The CAS Registry Mumber 146510-36-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,6,5,1 and 0 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 146510-36:
(8*1)+(7*4)+(6*6)+(5*5)+(4*1)+(3*0)+(2*3)+(1*6)=113
113 % 10 = 3
So 146510-36-3 is a valid CAS Registry Number.
146510-36-3Relevant articles and documents
Alternate synthesis of olanexidine base employing phase transfer catalysis
Khare, Lalit,Jain, Ratnesh,Dandekar, Prajakta
, (2021/11/13)
The traditional methods of synthesis of biguanide drugs generally result in the formation of high levels of waste. In this study, we have developed a simple and green route for the synthesis of olanexidine, the novel antimicrobial compound developed by Ot
AQUEOUS OLANEXIDINE SOLUTION, METHOD OF PREPARING THE SAME, AND DISINFECTANT
-
Page/Page column 6-7; 10, (2008/06/13)
The present invention provides a disinfectant that contains olanexidine in a concentration sufficient to exhibit an effective bactericidal effect, and that has hardly any side effects such as skin irritation. Specifically, the present invention provides a
